调节α-synuclein的传播和分解:帕金森病治疗中的影响
Beining Li1, Xue Xiao1, Mingxia Bi1
1School of Basic Medicine, Medical College of Qingdao University, Qingdao 266071, China.
Ageing research reviews
|May 8, 2024
概括
阿尔法-同核素 (α-Syn) 聚合驱动帕金森病 (PD) 神经退行. 这篇评论探讨了α-Syn.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔法-同核素 (α-Syn) 与帕金森病 (PD) 病原发生有内在联系.
- 病理性α-Syn形状和聚合到莱维体 (LBs) 中会导致神经毒性和神经退行,与布拉克阶段相对应.
- 目前的PD诊断缺乏早期生物标志物,治疗主要是治疗症状,而不是疾病进展.
研究的目的:
- 综合审查α-Syn在有关PD的生理和病理状态中的作用.
- 系统地分析α-Syn.的起源,分泌,聚合,传播和降解.
- 通过审查旨在减轻异常α-Syn聚合的候选药物来确定潜在的治疗点.
主要方法:
- 文献综述总结了关于α-Syn.的现有研究.
- 对α-Syn生命周期 (起源,分泌,聚合,传播,降解) 的系统分析.
- 对针对α-Syn.的治疗策略的临床前和临床研究的审查.
主要成果:
- 详细概述α-Syn的生理功能及其对PD的病理参与.
- 阐明α-Syn聚合和传播导致神经退行症的机制.
- 确定影响α-Syn处理和聚合的关键监管因素.
结论:
- 了解α-Syn的多方面的作用对于开发有效的PD疗法至关重要.
- 准α-Syn聚合通路为帕金森病提供了有前途的治疗途径.
- 对α-Syn调节和候选药物的进一步研究对于疾病修饰至关重要.
相关概念视频
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181


